Quality of life of elderly patients with solid tumours undergoing adjuvant cancer therapy: a systematic review

Karis Kin-Fong Cheng,1 Ethel Yee-Ting Lim,1 Ravindran Kanesvaran2

ABSTRACT

Objectives The measurement of quality of life (QoL) in elderly cancer population is increasingly being recognised as an important element of clinical decision-making and the evaluation of treatment outcome. This systematic review aimed to summarise the evidence of QoL during and after adjuvant therapy in elderly patients with cancer.

Methods A systematic search was conducted of studies published in CINAHL plus, CENTRAL, PubMed, PsycINFO and Web of Science from the inception of these databases to December 2016. Eligible studies included RCTs and non-RCTs in which QoL was measured in elderly patients (aged 65 years or above) with stage I–III solid tumours who were undergoing adjuvant chemotherapy and/or radiotherapy. Because of the heterogeneity and the insufficient data among the included studies, the results were synthesised narratively.

Results We included 4 RCTs and 14 non-RCTs on 1785 participants. In all four RCTs, the risk of bias was low or unclear for most items but high for detection. Of the 14 non-RCTs, 5 studies were judged to have a low or moderate risk of bias for all domains, and the other 9 studies had a serious risk of bias in at least one domain. The bias was observed mainly in the confounding and in the selection of participants for the study. For most elderly patients with breast cancer, the non-significant negative change in the QoL was transient. A significant increase in the QoL during the course of temozolomide in elderly patients with glioblastoma but a decreasing trend in QoL after radiotherapy was shown. This review also shows a uniform trend of stable or improved QoL during adjuvant therapy and at follow-up evaluations across the studies with prostate, colon or cervical cancer population.

Conclusions This review suggests that adjuvant chemotherapy and radiotherapy may not have detrimental effects on QoL in most elderly patients with solid tumours.

INTRODUCTION

In many countries, the incidence of cancer among older people is increasing. This increase can be attributed to the remarkable growth of the elderly demographic and the common pathophysiology of cancer and ageing.1 2 As a result, the demands for and the importance of broadening clinical trials to include older adults, incorporating geriatric-specific end points3 and integrating geriatric assessment to address the needs of individuals are also increasing.4 Although quality of life (QoL) is not formally a part of the geriatric assessment, the measurement of QoL in the elderly cancer population is increasingly being recognised as an important patient-reported outcome to complement the clinician’s evaluation of disease progression and the determination of the clinical benefit and the burden of cancer treatment, along with toxicity, survival and mortality rates. QoL is also considered a useful outcome measure to enhance patient-clinician communication and patient compliance in elderly patients with breast cancer during cancer treatment.5 In a short literature review, Wedding et al reported that elderly patients with cancer tend to perceive their QoL as more important than gains in survival when compared with younger patients.6 Nevertheless, our understanding of the effect of cancer treatment on the QoL of elderly patients remains very limited. Clinically, the decisions regarding cancer therapy and the clinical management of elderly patients with cancer may be complicated by their vulnerability to chemotoxicity and the pathological changes of ageing.

Strengths and limitations of this study

A systematic search of the published literature in major databases from their inception to December 2016 was conducted.

The risk of bias and the methodological aspects of quality of life reporting in the included studies were assessed.

The search of grey literature, unpublished studies, ongoing clinical trials and theses and dissertations were not conducted.

The studies included in this review are mainly non-randomised controlled trials.

The meta-analysis was not conducted to pool the data and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was not used to assess the quality of evidence of the included studies.

To cite: Cheng KK-F, Lim EYT, Kanesvaran R. Quality of life of elderly patients with solid tumours undergoing adjuvant cancer therapy: a systematic review. BMJ Open 2018;8:e018101. doi:10.1136/bmjopen-2017-018101

Correspondence to Professor Karis Kin-Fong Cheng; nurckfk@nus.edu.sg

Received 7 June 2017
Revised 31 October 2017
Accepted 9 November 2017

1 Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, National University Health System, Singapore, Singapore

2 National Cancer Centre Singapore, Singapore, Singapore

*Correspondence to Professor Karis Kin-Fong Cheng; nurckfk@nus.edu.sg
together with different considerations of the treatment benefit and harm margins, functional decline, tolerability and QoL issues. A univariate analysis by Externemann et al revealed an association of the QoL effect with dose modification of chemotherapy in older patients. The literature states that elderly patients with cancer are less likely than their younger counterparts to be treated with a full course of adjuvant chemotherapy and radiotherapy. Consideration should be given to approaches that can prolong life expectancy, but not at the expense of QoL. For cancers with an extremely poor prognosis, such as glioblastoma, the extension of survival is less clinically meaningful if the patient has a decline in QoL. Researchers have also suggested that QoL be used as the main end point to support clinical decision-making if different cancer treatments are equally effective in terms of survival. To the best of our knowledge, a systematic review of the effects of adjuvant therapy on the QoL of elderly patients with cancer has not yet been published. Therefore, we undertook a systematic review of the literature to summarise the evidence of global or overall QoL and other domains pertaining to QoL during and after adjuvant therapy in elderly patients with stage I–III solid tumours. We considered the following question: ‘Does the global or overall QoL during and after adjuvant chemotherapy and/or radiotherapy decline, maintain or improve from baseline in elderly patients with solid tumours in randomised controlled trials (RCTs) or non-RCTs?’ In this review, QoL refers to the health-related QoL of elderly patients, considering the corresponding global, physical, cognitive, psychological and social domains as affected by the adjuvant therapy.

METHODS
The methodology of this systematic review included a prespecified literature search strategy, inclusion and exclusion criteria, process for selecting studies, assessment of methodological quality of studies and data synthesis. The review protocol was not registered in an international registry. The conduct and reporting of this systematic review were in accordance with the planned review methods except for the addition of assessment of risk of bias (RoB) of the included studies using the Cochrane Risk of Bias tool for RCTs and Risk of Bias tool in Non-Randomised Studies of Interventions (ROBINS-I) for non-RCTs.

Literature search strategy
A systematic electronic search of peer-reviewed English-language articles published in CINAHL plus (1937–2016), CENTRAL (1993–2016), PubMed (1996–2016), PsycINFO (1967–2016) and Web of Science (1900–2016) from the inception of these databases to December 2016 was conducted. The date last searched was in March 2017. Searches were limited to human studies published in English. A pilot search on CINAHL was performed to identify the relevant keywords contained in the title, abstract and subject descriptors. Three broad categories of concepts were searched: ‘elderly’, ‘cancer’ and ‘quality of life’. The search terms included (older* OR elder* OR geriatric OR gerontology* OR senior OR aged) AND (oncology OR cancer* OR neoplasm*) AND (quality of life OR QOL). The full electronic search strategy is presented in Appendix A. The reference lists of the included articles were also examined to identify additional eligible articles.

Study selection
Inclusion criteria
We included RCTs and non-RCTs in which QoL was measured in elderly patients (aged 65 years or above) with stage I–III solid tumours who were undergoing adjuvant chemotherapy and/or radiotherapy. Non-RCTs include quantitative studies such as observational, before-and-after and longitudinal studies, in which the allocation of intervention (analogy of treatment) occurs during the course of the usual treatment decisions. We required that the baseline and at least one global or overall QoL data element during and/or after adjuvant chemotherapy and/or radiotherapy be collected and reported in the studies so as to allow an in-context comparison of before and after adjuvant therapy. Studies that covered heterogeneous age groups were included if a subgroup analysis was performed and reported for those aged 65 years or above.

Exclusion criteria
Studies were excluded if they involved patients with haematological malignancies, distant metastatic cancer or recurrent cancer without a separate analysis and report of solid tumours or non-metastatic/regional metastatic cancer. We also excluded case reports, qualitative studies, literature reviews, studies that evaluated surgical or procedure-related treatment and presented in abstract form.

Process for selecting studies
We screened articles obtained from keyword searching for duplicates electronically with End-Note and then manually. After duplicate removal, we assessed the remaining articles for eligibility based on titles and abstracts. We included studies in full-text screening if they were RCTs or non-RCTs, included elderly patients with stage I–III solid tumours who were undergoing adjuvant chemotherapy and/or radiotherapy, and reported QoL. We retrieved full-text articles if we considered the studies relevant and if there was insufficient information to determine eligibility. We then examined each full-text article against the inclusion and exclusion criteria of the review.

Data extraction
We extracted data related to publication information, sample characteristics, type of cancer, type of adjuvant chemotherapy and/or radiotherapy, supportive care, QoL measurements and results, dropouts and authors’ conclusions. Functional status and comorbidities at baseline and
therapy-related adverse effects (where reported) were also extracted because of concern that they might co-vary or confound with those of adjuvant therapy to alter the change of QoL.

**Assessment of methodological quality of studies on QoL**

The methodological quality of the included studies on QoL was assessed using a checklist of predefined criteria for studies on QoL. The checklist was originally developed to assess the internal and external validity of prognostic studies and was modified to assess the methodological aspects of QoL reporting in later studies. The methodological quality of the included studies on QoL was assessed using a checklist of predefined criteria for studies on QoL. The checklist covers the following 14 items: sampling (two items), selection of QoL measurement (one item), data collection process (two items), response rate (two items), group comparison (one item), clarity of reporting (five items) and determination of prognostic factors (one item), all of which are important in QoL studies. For each item, a score of 1 or 0 was given; 1 was assigned to an item meeting the methodological criteria, while 0 was assigned if an item neither met the criteria nor described the related parameter sufficiently. The possible score ranged from 0 to 14, with scores of 10 or above, 7 to 9 and 6 or less indicating high, moderate and low quality, respectively.

**Assessment of risk of bias**

The RoB of the included studies was evaluated using the Cochrane RoB tool and ROBINS-I for RCTs and non-RCTs, respectively. Both tools are domain-based evaluations of RoB with respect to the internal validity of studies. The Cochrane RoB tool covers the domains of selection, performance, detection, attrition and reporting bias, and other sources of bias. A judgement of ‘yes’ indicates a low RoB; ‘no’, a high RoB and ‘unclear’, either an unclear or unknown RoB. The ROBINS-I tool covers seven domains: bias due to confounding; bias in selection of participants into the study; bias in classification of interventions; bias due to deviations from intended interventions; bias due to missing data; bias in measurement of outcomes and bias in selection of the reported results. The RoB judgements within each domain are categorised as ‘low risk’ if the study is comparable to a well-performed RCT, ‘moderate risk’ if the study is sound but cannot be considered comparable to a well-performed RCT, ‘serious risk’ if the study has some considerable problems, ‘critical risk’ if the study is too problematic and ‘no information’. The judgements within each domain contribute to the overall RoB.

In this review, two reviewers (LEYT and TDRL) independently performed the literature search, eligibility assessments and study selection. The data extraction, methodological quality assessment and the RoB evaluation were conducted by CKKF and LEYT. Discrepancies and disagreements were discussed and resolved by consensus.

**Data synthesis**

Because of the variations in study design, cancer populations and QoL scales and the insufficient data among the included studies, a meta-analysis was deemed impossible, and the results were synthesised narratively taking into account of the RoB of individual studies. In addition, we report a change in QoL scores from baseline to the middle of and to the completion of adjuvant therapy, and to the post-treatment follow-up period of individual studies where data were available. We defined ‘0’ as no change, ‘↑’ denotes better QoL than baseline and ‘↓’ represents worse QoL than baseline. The effect size (ES) was also calculated for individual studies for which sufficient information was available: 0.2 to <0.5 was considered small, 0.5 to <0.8 moderate and ≥0.8 large.

**RESULTS**

**Search results**

The initial search identified 56,935 articles, of which 440 were considered potentially relevant after checking for duplicates and title and abstract screening. After full-text assessment of the 440 articles, 18 met the eligibility criteria for inclusion in the review and analysis (figure 1). In most cases, the articles were excluded mainly because of the lack of QoL assessment during adjuvant therapy, a separate report of participants aged 65 years or above and/or a separate report of the QoL of participants who were undergoing adjuvant therapy or suffering from non-metastatic cancer.

**Description of studies**

Eleven studies were published between 2000 and 2009, and seven between 2010 and 2015. With respect to the country of origin, 10 were from Europe, 4 from the USA, 2 from South Korea and 1 from Canada; the other was a multicountry study. As for the study design, 13 studies were non-RCTs (before-and-after or longitudinal studies) that assessed the QoL of patients who were undergoing adjuvant chemotherapy, radiotherapy or concomitant chemotherapy and radiotherapy. Four were RCTs; two of these compared the effects of different chemotherapy regimens on QoL, one study compared the effects of chemotherapy and hormonal therapy against those of hormonal therapy alone on QoL and the other compared the effects of radiotherapy and supportive care with those of supportive care alone on QoL. One was a validation study that involved a QoL evaluation of participants who were undergoing radiotherapy with or without hormonal therapy.

The sample size of participants aged 65 years or older was reported by 17 of the 18 studies; Caffo et al did not separately report the number of participants aged 65 years and older. The sample sizes ranged from 11 to 368 per study. In all, these 17 studies included 1785 participants; 764 participants from RCTs and 1021 participants from non-RCTs. Of these 1785 participants, 1633 completed the baseline QoL questionnaire; 671 participants from RCTs and 962 participants from non-RCTs. Furthermore, the baseline completion rates ranged from 64.7% to 100%. Where reported, the age range of participants was reported to be 30–85 years.
range of the participants was 65–92 years.\textsuperscript{16,17,19,20,22,24,28,31–33} Ele

Eleven studies included participants aged 80 years and older.\textsuperscript{16,20,22,24,25,27,28,30–33} As for the cancer diagnosis, eight studies included participants with breast cancer,\textsuperscript{16–23} four studies focused on glioblastoma participants,\textsuperscript{24–27} and two studies considered participants with colon cancer.\textsuperscript{30,31} We included one study each on mixed,\textsuperscript{28} prostate,\textsuperscript{29} cervical\textsuperscript{32} and lung cancer\textsuperscript{33} participants.

The most frequently used QoL instrument was the European Organization for Research and Treatment of Cancer general questionnaire (EORTC QLQ-C30; 13 studies).\textsuperscript{16,17,21–31} Nine studies also used a disease-specific QoL instrument along with the EORTC QLQ-C30 for breast,\textsuperscript{16,17,21–25} brain\textsuperscript{24,25,27} and lung\textsuperscript{33} cancer populations. The follow-up QoL evaluation was conducted at various intervals during adjuvant therapy and the post-treatment

---

**Figure 1** Study flow diagram. CT, chemotherapy; QoL, quality of life; RT, radiotherapy.
| Study /country | Type of study | Age (years) | Sample size (≥65 years cohort) | No. of participants completed baseline QoL measurement (%) | Gender (% female) | Type of cancer | CT/RT | Measurement of CGA domains | Measurement of CT/RT-related toxicity/adverse effect | QoL scale (domains/subscales and score ranges) | QoL measurement time point |
|---------------|--------------|-------------|-------------------------------|----------------------------------------------------------|------------------|---------------|-------|-----------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------|
| Arraras et al (2008a), Spain | Descriptive longitudinal | 72.3±5.7 (range 65–87) | 48 | 48 (100) | 100 | Breast (stage I–III) | RT, loco-regional, regional (no details on dosage) | KPS Comorbidity Daily activities | Selected items from NCI-CTCAE | EORTC QLQ-C30 (50 items—overall QoL, physical, role, cognitive, emotional and social functioning scales; fatigue, nausea/vomiting and pain symptom scales; five single-item assessing additional symptoms and one single-item assessing perceived financial impact; all scales and single-item measure scores are transformed to a scale of 0–100, a higher score for the QoL/functioning and a higher score on a symptom scale/item represents a worse level of symptom) EORTC QLQ-BR23 (23 items—symptoms and side effects related to different treatment modalities, body image, sexuality and future perspective specific to breast cancer; all items and scale scores are transformed to a 0–100 scale, a higher score for the functional scale indicates a better level of functioning and a higher score on a symptom scale/item represents a worse level of symptom) | First day of RT • Last day of RT • 6 weeks after RT |
| Arraras et al (2008b), Spain | RCT (longitudinal) | No information on mean age (range 65–77) | 39 | 39 (100) | 100 | Breast (stage I–IIIa) | FEC: fluorouracil 600 mg/m², epirubicin 75 mg/m², cyclophosphamide 600 mg/m² for six cycles or CMF: cyclophosphamide 100 mg/m², methotrexate 40 mg/m², fluorouracil 600 mg/m² for six cycles (30 women also had the CT combined with RT; a 5-week RT course starting 3–4 weeks after CT) | Comorbidity | Modified WHO toxicity criteria PACSIS (a single-item measure—assessing the amount of effort it costs to cope with illness which influences subjective well-being and QoL; score range 0–100*) | EORTC QLQ-C30 | Baseline • 1 week after first, second, third and last cycle of CT • 4 months post-CT |
| Browall et al (2008), Sweden | Descriptive longitudinal | No information on mean age (range 65–77) | 39 | 39 (100) | 100 | Breast (stage I–IIIa) | FEC: fluorouracil 600 mg/m², epirubicin 75 mg/m², cyclophosphamide 600 mg/m² for six cycles or CMF: cyclophosphamide 100 mg/m², methotrexate 40 mg/m², fluorouracil 600 mg/m² for six cycles (30 women also had the CT combined with RT; a 5-week RT course starting 3–4 weeks after CT) | Comorbidity | Modified WHO toxicity criteria PACSIS (a single-item measure—assessing the amount of effort it costs to cope with illness which influences subjective well-being and QoL; score range 0–100*) | EORTC QLQ-C30 | Baseline • 1 week after first, second, third and last cycle of CT • 4 months post-CT |
| Crivellari et al (2000), multicountries | Descriptive longitudinal | No information on mean age (age ≥65 years) | 76 | 58 (76.3) | 100 | Breast (stage I–III) | Tamoxifen for 5 years or Tamoxifen plus three early courses of CMF: cyclophosphamide 100 mg/m², methotrexate 40 mg/m², fluorouracil 600 mg/m² every 28 days for four cycles | ECOG Comorbidity | Modified WHO toxicity criteria PACSIS (a single-item measure—assessing the amount of effort it costs to cope with illness which influences subjective well-being and QoL; score range 0–100*) | EORTC QLQ-C30 | Baseline • 2 months after first day of adjuvant therapy then every 3 months until 24 months |
| Dees et al (2000), USA | Descriptive longitudinal | 71.4 (range 65–79) | 17 | 11 (64.7) | 100 | Breast (early stage) | AC: doxorubicin 60 mg/m², cyclophosphamide 600 mg/m² for four cycles | Myelosuppression Cardiotoxicity | BCOG (50 items—overall QoL; consequences of alopecia, positive well-being, physical symptoms, inconvenience associated with treatment, fatigue, emotional dysfunction and nausea sub-scales; score range 0–10*) | Day 1 of each cycle • 2 months after completing CT • 6 months after completing CT |
| Dees et al (2000), USA | Descriptive longitudinal | 71.4 (range 65–79) | 17 | 11 (64.7) | 100 | Breast (early stage) | AC: doxorubicin 60 mg/m², cyclophosphamide 600 mg/m² for four cycles | Myelosuppression Cardiotoxicity | BC04 (50 items—overall QoL; consequences of alopecia, positive well-being, physical symptoms, inconvenience associated with treatment, fatigue, emotional dysfunction and nausea sub-scales; score range 0–10*) | Day 1 of each cycle • 2 months after completing CT • 6 months after completing CT |
| Study/country          | Type of study | Age (years) Means±SD | Sample size (≥65 years cohort) | No. of participants completed baseline QoL measurement (%) | Gender (% female) | Type of cancer | CT/RT | Measurement of CGA domains | Measurement of CT/RT-related toxicity/adverse effect | QoL scale (domains/subscales and score ranges) | QoL measurement time point |
|-----------------------|---------------|-----------------------|--------------------------------|----------------------------------------------------------|-------------------|----------------|-------|----------------------------|-------------------------------------------------|-------------------------------------------------|-----------------------------|
| Hurria et al (2006), USA | Descriptive longitudinal | 68 (range 65–84) | 49 | 49 (100) | 100 | Breast (stage I–III) | CMF: cyclophosphamide 600 mg/m², methotrexate 40 mg/m², 5-fluorouracil 600 mg/m² every 3 weeks for eight cycles or AC: doxorubicin 60 mg/m², cyclophosphamide 600 mg/m² every 2 or 3 weeks for four cycles or ACT: AC followed by paclitaxel 175 mg/m² every 2 or 3 weeks for four cycles or AC followed by paclitaxel 17.5 mg/m² weekly for 12 cycles or ACT-H: ACT followed by trastuzumab 2 mg/kg weekly for 52 weeks (CT regimen was at the discretion of the treating physician) | CCI ADL IADL MMSE GDS BMI | FACT-B (44 items covering FACT-General plus the Breast Cancer Subscale—overall QoL; total FACT-B score including all the subscales, score range 0–144); breast well-being (score range 0–26), emotional well-being (score range 0–24), functional well-being (score range 0–28), physical well-being (score range 0–28) and social well-being subscales (score range 0–28) | Prior to CT  On completion of CT 6 months after CT |
| Kornblith et al (2011), USA | RCT (longitudinal) (QoL was a substudy) | Standard CT (CMF or AC) group 72±4.6 Capecitabine group 72±5.0 | 350 | 326 (93.1) | 100 | Breast (stage I–III) | Standard CT CMF: cyclophosphamide 100 mg/m² from days 1 to 14, methotrexate 40 mg/m² and 5-fluorouracil 600 mg/m² on days 1 and 8 for six cycles or AC: adriamycin 60 mg/m², cyclophosphamide 600 mg/m² on day 1 for four cycles or test cytotoxic drug Capecitabine 2000 mg/m² for 14 days; dose increased to 2500 mg/m² if no toxic effect after first cycle for six cycles | ECOG OARs (comorbidity) HADS BOMC Neurobehavioural Functioning and Activities of Living Scale Social Support Survey | NCI CTCAE Systemic adverse effects subscale of EORTC BR23† EORTC QLQ-C30 EORTC QLQ-BR23† | Baseline  Mid-CT (about day 77 for CMF, day 29 for AC, day 63 for capecitabine)  Post-CT (6–7 months for CMF, 4–5 months for AC and capecitabine) 12 months postbaseline 18 months postbaseline 24 months postbaseline |
| Watters et al (2003), Canada | Descriptive longitudinal | 70±5 (range 65 to 80) | 20 | 16 (80) | 100 | Breast (stage I–III) | Anthracycline-based adjuvant CT Fluorouracil 500 mg/m², doxorubicin 50 mg/m², cyclophosphamide 500 mg/m² at 21 days interval for six cycles | KPS | EORTC QLQ-C30 EORTC QLQ-BR23† SF-36† (36 items – physical functioning, role limitations because of physical health problems, bodily pain, social functioning, general mental health, role limitations because of emotional health problems, vitality and general health perceptions domains; all domain scores are transformed to a scale of 0–100; these domain scores then combined to calculate the physical and mental component scores; score range 0–100) | Prior to CT  Before the third cycle  Completion of CT 6 months post-CT |
| Study / country | Type of study | Age (years) | Sample size | Sample size cohort | No. of participants completed baseline QoL measurement (%) | Gender (%) Type of cancer | CT/RT | Measurement of QoL scale (domains/subscales and score ranges) | Measurement of toxicity/adverse effect | QoL measurement time point |
|----------------|---------------|-------------|--------------|-------------------|-------------------------------------------------|--------------------------|--------|----------------------------------------------------------------|----------------------------------|-------------------------------|
| Perrone et al (2015), Italy | RCT (longitudinal) | CMF: median 71 (range 65–79) | 299 | 252 (84.3) | 100 Breast (stage I–III) | CMF: cyclophosphamide 600 mg/m², methotrexate 40 mg/m², fluorouracil 600 mg/m² on days 1 and 8 every 4 weeks for 4 or 6 cycles or docetaxel 35 mg/m² on days 1, 8 and 15 every 4 weeks for four or six cycles | ECOG CCI ADL IADL | EORTC QLQ-C30† EORTC QLQ-BR23† | •Baseline | Period of temozolomide period due to poor prognosis |
| Gállego Pérez-Larraya et al (2011), France | Descriptive longitudinal (phase II trial) | Median 77 (range 70–87) | 70 | 59 (84.3) | 60 Glioblastoma | Temozolomide (150–200 mg/m² for 5 days every 4 weeks for 12 cycles until disease progression) (adjusted based on toxicity) | KPS (<70 as eligibility criteria) MMSE | EORTC QLQ-C30† EORTC QLQ-BN20† | •Baseline | At least every month (restricted to the period of temozolomide period due to poor prognosis) |
| Kerne-Guibert et al (2007), France | RCT (longitudinal) | Supportive care+RT group Median 75 (range 70–84) | 39 | 35 (89.7) | 37 Glioblastoma | Supportive care (corticosteroids and anticonvulsant agents, physical and psychological support, management by a palliative care team) and RT (1.8 Gy given 5 days per week, total dose of 50 Gy) | KPS (<70 as eligibility criteria) MMSE | EORTC QLQ-C30† EORTC QLQ-BN20† | •Baseline | Day 30 Day 60 Day 90 Day 135 |
| Minniti et al (2009), Italy | Descriptive longitudinal | Median 73 (range 70–79) | 43 | 36 (83.7) | 51.2 Glioblastoma | Focal hypofractionated RT (total dose of 30 Gy in 6 fractions over 2 weeks) followed by adjuvant temozolomide 5 days every 28 days up to 12 cycles; 150 mg/m² for first cycle and adjusted based on toxicity for subsequent cycles | KPS (<50 as eligibility criteria) Comorbidity | EORTC QLQ-C30† | •Before RT | •After RT | •second, fourth & sixth cycles of temozolomide |
| Minniti et al (2013), Italy | Descriptive longitudinal (phase II trial) | Median 73 (range 70–81) | 71 | 65 (91.5) | 49.2 Glioblastoma | Focal hypofractionated RT (total dose of 40 Gy in 15 fractions) plus concomitant temozolomide 75 mg/m² (given 7 days/week followed by adjuvant temozolomide 5 days every 28 days for 12 cycles (adjuvant was started 4 weeks after the completion of RT); 150 mg/m² for first cycle and 200 mg/m² from second cycle onwards | KPS MMSE NR | EORTC QLQ-C30† EORTC QLQ-BN20† | •Before RT | •4 weeks after RT (before the start of adjuvant temozolomide) | •Every 8 weeks during treatment until disease progression |
Table 1  Continued

| Study /country | Type of study | Age (years) Mean±SD | Sample size (≥65 years cohort) | No. of participants completed baseline QoL measurement (%) | Gender (% female) | Type of cancer | CT/RT | Measurement of CGA domains | Measurement of CT/RT-related toxicity/adverse effect | QoL scale (domains/subscales and score ranges) | QoL measurement time point |
|----------------|---------------|---------------------|-------------------------------|----------------------------------------------------------|------------------|----------------|-------|-----------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------|
| Mohile et al (2011),28 USA | Descriptive before/after | Median 74.1 (range 65–92) | 368 | 368 (100) | 58.4 | Breast (17.1%) | RT | Median total dose of 57.6 Gy (range 30–101) | NR | EORTC QLQ-C30 | Before RT *During the last week of RT |
| Anrasas et al (2008b),29 Spain | Descriptive longitudinal (validation) | 70.9±5.2 | 137 | 137 (100) | 0 | Prostate (localised) | Lower risk: RT alone (total dose of 72 Gy) Intermediate risk: neoadjuvant and concomitant combination of an anti-androgen and an LHRH analogue (6 months)+RT (total dose of 76 Gy) High risk: neoadjuvant and concomitant combination of an anti-androgen and an LHRH analogue (6 months)+RT (total dose of 76 Gy)+adjuvant LHRH analogue | KPS | NR | EORTC QLQ-C30 | First day of RT *Last day of RT *6 weeks after RT |
| Bouvier et al (2008),30 France | Descriptive longitudinal survey | No information on mean age (range 75–85+) | 11 (only) | 11 (100) | NR | Colon | Fluorouracil or capecitabine (oral, 750–1250 mg/m², twice daily on days 1–14 every 3 weeks for eight cycles) (dose level was determined a/c toxicity effects during the first and preceding cycles) | NR | EORTC QLQ-C30 | At the time of diagnosis *3 months after diagnosis *6 months after diagnosis (CT was given within 6 months after surgery) *12 months after diagnosis |
| Chang et al (2012),31 South Korea | Descriptive longitudinal | Median 74.5 (range 70–90) | 82 | 57 (69.5) | 64 | Colon (stage II–III) | CPT-11 (oral, 750–1250 mg/m², twice daily on days 1–14 every 3 weeks for eight cycles) (dose level was determined on the basis of toxicity effects during the first and preceding cycles) | ECOG PS 0–2 as eligibility criteria | CACI | EORTC QLQ-C30 | Baseline *6 months during CT *6 months after completion of CT |
### Table 1: Continued

| Study/country | Type of study | Age (years) | Sample size (≥65 years cohort) | No. of participants completed baseline QoL measurement (%) | Gender (% female) | Type of cancer | CT/RT | Measurement of CGA domains | Measurement of CT/RT-related toxicity/adverse effect | QoL scale (domains/subscales and score ranges) | QoL measurement time point |
|---------------|---------------|-------------|-------------------------------|--------------------------------------------------------|-------------------|----------------|-------|-----------------------------|-----------------------------------------------|-----------------------------------------------------------------|--------------------------|
| Caffo et al (2003), 26 Italy | Descriptive longitudinal | Median 62.5 (range 46–81) | 25 (no information on the breakdown of sample size by age group) | - | 100 | Cervical endometrium | Postoperative pelvic RT (median total dose of 45.6 Gy, at a dose of 1.8–2.0 Gy five times/week) | NR | Diarrhoea | Diary card (12 items—global QoL, physical side effects observed during external pelvic RT, daily activities and psychological well-being; score range 1–4, with higher scores of QoL, psychological well-being and daily activities indicating better condition and higher scores on symptoms reflecting intense symptoms) EORTC QLQ-C30 | At the start of RT • Daily during RT period (reported as mean weekly scores) EORTC QLQ-C30: • Before RT • After RT |
| Park et al (2013), 27 South Korea | Descriptive longitudinal | Median 69 (range 65–82) | 66 | 66 (100) | 9.1 | Non-small-cell lung carcinoma (completely resected stage Ibl, II or IIIa) | NP: cisplatin 80 mg/m² on day 1, vinorelbine 25 mg/m² on days 1 and 8 at 3-week interval for four cycles (n=30, 45.5%) or PC: carboplatin, paclitaxel 175 mg/m² on day 1 at 3-week interval for four cycles (n=36, 54.5%) (at the physician’s discretion) | ECOG Comorbidity NCI CTCAE EORTC QLQ-C30 EORTC QLQ-LC13 (13 items—lung cancer-related symptoms, treatment-related adverse effects and the use of pain medication; all items and scale scores are transformed to a 0–100 scale, with higher scores of functioning indicating greater functioning and higher scores on symptoms reflecting worse symptoms) | Before first dose of CT at each cycle • 1 month after fourth cycle |

*Higher scores indicating better quality of life unless specified otherwise.
†Quality of life is the secondary end point if indicated.
BCCQ, Breast Cancer Chemotherapy Questionnaire; CGA, Comprehensive Geriatric Assessment; CT, chemotherapy; EORTC QLQ-BN20, European Organization for Research and Treatment of Cancer-specific module for brain cancer; EORTC QLQ-SP03, European Organization for Research and Treatment of Cancer-specific module for breast cancer; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer QLQ-C30 general questionnaire; EORTC QLQ-LC13, European Organization for Research and Treatment of Cancer for lung-specific questionnaire; FACT-B, Functional Assessment of Cancer Therapy-Breast cancer; NR, not reported; FACIS, perceived adjustment to chronic illness scale; GoL, quality of life; RCT, randomised controlled trial; RT, radiotherapy; SF-36, 36-item short-form survey.
period. Ten studies reported at least one QoL evaluation during adjuvant therapy,17–19 21–25 31 32 and five evaluated QoL immediately after the completion of adjuvant therapy.20–22 28 29 The timing of the QoL evaluation after adjuvant therapy ranged from 1 month after treatment to 24 months after the first day of adjuvant therapy. Ten studies followed participants for 6 months or less after the completion of adjuvant therapy.16 17 19 20 22 25 29–31 33 Two studies included a QoL evaluation of 24 months after the first day of chemotherapy.18 21

The geriatric domains of functional status and/or comorbidities at baseline were examined and reported in 14 studies.16–18 20–27 29 31 33 As shown in table 2, two studies reported the mean score of the Karnofsky Performance Scale (KPS) as 90 or above,16 29 whereas three reported the median score of the KPS as 70 or above at baseline.25–27 A KPS score of <70 was used as a cut-off for the recruitment criterion in one study.24

Comorbid conditions were reported in eight studies,16 17 20 21 23 26 31 33, six of these involved participants with a limiting comorbidity or with three or more comorbidities.16 17 21 23 31 33 Twelve studies measured cancer therapy-related toxicity during adjuvant therapy,16 18–21 23–26 31–33, and nine of these used National Cancer Institute’s Common Terminology Criteria for Adverse Events.16 20 21 23–26 31 33 With respect to haematological toxicity, two studies reported grade 3 or 4 toxicity in fewer than 10% of participants,18 31 and five reported such toxicity in 25% or higher during adjuvant chemotherapy or concomitant radiotherapy and chemotherapy.20–23 26 33 With respect to non-haematological toxicity, a study reported grade 3 or 4 toxicity in fewer than 10% of participants,18 and four reported such toxicity in 25% or higher during adjuvant chemotherapy or concomitant radiotherapy and chemotherapy20–23 26 31 (table 2).

Methodological quality

Thirteen studies attained scores of 10 or higher (high quality),16–27 29 31 three scored 7–9 (moderate quality)28 30 31 and two scored 6 or lower (low quality).20 32 The main methodological drawbacks of the included studies were the lack of determination of the prognostic factors for QoL (100%) and the lack of data on the time since diagnosis or treatment (77.8%) and the characteristics of non-responders (77.8%) (table 3).

Risk of bias

Randomised controlled trials

In all four RCTs, the RoB was low or unclear for most items but high for detection because of the subjective and self-reporting nature of the QoL assessment. One RCT did not blind the participants and staff and thus was judged to have a high risk of performance bias.18 The remaining three RCTs did not report information on the blinding of participants and personnel to allow for a judgement of the performance bias.21 23 25 We judged three RCTs to have an unclear risk of attrition bias because of the lack of explicit information on patients’ lost to follow-up and missing data.18 21 25 (figure 2).

Non-randomised controlled trials

Of the 14 non-RCTs, five studies were judged to have a low or moderate RoB for all domains,16 20 26 31 33 and the other nine studies had a serious RoB in at least one domain.17 19 24–28 30 33 The bias was observed mainly in the confounding, in the selection of participants for the study and in the measurement of outcomes. Although most of the studies measured some confounding factors (eg, functional performance status or comorbidity) at baseline, no stratification in the study design or adjustment in the data analysis was made to control their effects.16 17 20 22–24 27 29 31 33

Four non-RCTs did not measure functional performance status or comorbidities at baseline.19 28 30 33 The bias in the selection of participants was either moderate or serious in all the non-RCTs.16 17 19 20 22–24 27–33 Only fit and functional elderly patients seemed to have been enrolled in these studies, and hence, the study cohorts might not be representative of the real-world population. Like the RCTs, all 14 non-RCTs had a moderate-to-serious RoB in the measurement outcomes because of the subjective and self-reporting nature of the QoL assessment. The bias in the selection of reported results was unclear in all the non-RCTs because of unavailability of study protocols.16 17 19 20 22–24 27–33 (table 4).

QoL outcomes

Breast cancer

EORTC-QLQ-C30

Three studies reported the global QoL scores at baseline, during chemotherapy, at the time of completion of chemotherapy and 4–12 months after the completion of chemotherapy.17 21 22 The participants in these studies were treated with the standard chemotherapy regimen for breast cancer, including an anthracycline-based, cyclophosphamide/methotrexate/fluorouracil (CMF) or fluorouracil/epirubicin/cyclophosphamide regimen. In the study by Kornblith et al,21 approximately half of the participants received capecitabine. Browall et al reported statistically significantly lower global QoL scores during (ES, 0.74) and immediately after the completion (ES, 0.71) of chemotherapy than at baseline and a non-significant decline in the global QoL score 4 months after chemotherapy.17 Watters et al also revealed a statistically significantly lower global QoL score immediately after the completion of chemotherapy (ES, 0.66) than at baseline and a non-significant decline in the global QoL scores during and 6 months after chemotherapy.22 Browall et al and Watters et al also reported the domain scores, wherein statistically significantly lower scores in the role and social functioning domains were found immediately after the completion of chemotherapy than at baseline. No significant reductions in role and social well-being were reported during or 4–6 months after the completion of chemotherapy.17 22 Emotion was the only domain that showed an improvement from baseline to the follow-up evaluations, with a statistically significantly higher score during chemotherapy. The domains of physical and cognitive functioning revealed no statistically significant differences across time.17 22 In the study by Kornblith et al, both

Cheng KK-F, et al. BMJ Open 2018;8:e018101. doi:10.1136/bmjopen-2017-018101
Table 2  Summary of the main findings of QoL

| Study | Functional status at baseline (functional status during adjuvant therapy if reported) | Comorbid condition at baseline | Toxicity/adverse effect | Supportive care where reported | Global or overall QoL scores (scale range) | Global or overall QoL scores Adjuvant chemotherapy and/or radiotherapy | Findings of global or overall QoL (Other QoL domains/subscales if reported) | Authors’ conclusions |
|-------|--------------------------------------------------------------------------------------|-------------------------------|-------------------------|--------------------------------|------------------------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Arraras 2008a 16 | KPS mean 94.9 During therapy: KPS decreased from baseline to last dose of RT (mean difference 4.7 (0–100) but returned to baseline 6weeks after RT) | Limiting comorbidity 62.5% | At last day of RT: Levels 2-3 skin toxicity 8.4% Level2 dysphagia 4.2% Level2 fatigue 4.2% Level2 pain 2.1% | NR | Global QoL (0–100) 59.5±12 n=48 | 56.4±11.2 n=48 66.5±14.8 (6weeks after RT) n=46 | ◄ Global QoL improved significantly from baseline to final evaluation* Subscales ► Significant worsening in physical and role functioning, and fatigue, pain and breast symptoms in last day of RT but improved at 6weeks after RT (final evaluation)* | ◄ Global QoL data indicate RT was well tolerated by elderly women with localised breast cancer |
| Browall 2008 17 | NR | one or two comorbidity 61% ≥3comorbidities 3% | NR | Global QoL (0–100) 76±20 n=39 | 60±23 n=35 61±22 n=32 70±24 (6months after CT and about 7 weeks after RT) n=30 | ◄ Global QoL decreased significantly from baseline to midtreatment and last dose of CT. The decrease in global health status had not fully recovered to baseline level at 4months post-CT* Subscales ► Physical, role, social and cognitive functioning decreased significantly from baseline to last dose of CT ► The decrease in physical and role functioning had not fully recovered to baseline levels at 4months post-CT ► No significant change in future perspective, emotional and sexual functioning over time | ◄ There was a significant decrease in global QoL, body image, physical & role functioning during and after CT, but the decrease was independent of age |
| Crivellari 2000 18 | ECOG ≤2 for participants to be eligible | No specific data reported for those 58 participants who completed baseline QoL measurement | Grade 3 haematological toxicity 9.2% Other grade 3 toxicity 6.6% | NR | Perceived adjustment to chronic illness QoL (0–100) Median 69 n=58 (CMF plus tamoxifen) | Median 68 n=55 | Median 62 (18 months after first day of CT) n=55 | ◄ QoL improved progressively across study points (within CMF plus tamoxifen group) Subscales ► Adding CMF to tamoxifen provided little survival benefits for the older patients, and patients continued to report more effort to cope (low QoL) in the tamoxifen plus CMF group compared with the tamoxifen alone group across time ► CMF tolerability and effectiveness were reduced for elderly patients with breast cancer |
| Deves 2000 19 | NR | NR | Neutropenic complications and alteration in cardiac function were not significantly age related, no clinically significant age-related trends in toxicity | Overall QoL (0–10) 7.65±0.88 n=11 | 6.63±1.48 n=7 (authors mentioned to collect data at 2 and 6 months after completing CT, but they did not report the results/data) | ◄ Overall QoL decreased from baseline to last dose of CT but not significant | ◄ There was no evidence of decline QoL in older patients with breast cancer treated with adjuvant AC compared with younger ones |

Continued
### Table 2 Continued

| Study | No. of participants | Comorbid condition at baseline | Functional status at baseline (functional status during adjuvant therapy if reported) | Toxicity/adverse effect | Supportive care where reported | Global or overall QoL scores (range/scale) | Findings of global or overall QoL (Other QoL domains/subscales if reported) | Authors’ conclusions |
|-------|---------------------|-------------------------------|-----------------------------------------------------------------|------------------------|---------------------------------|------------------------------------------|--------------------------------------------------------------------------------|---------------------|
| Hurria 2006<sup>10</sup> | NR                  | CCI mean 3                    | Grade 3 or 4 haematological toxicity 27% Grade 3 or 4 non-haematological toxicity 31% | NR                     | Overall QoL (0–148) n=116 | 116 (no information on SD) n=49 | No significant longitudinal change in overall QoL across all time points Subscales | No significant longitudinal change in physical, social, emotional and functional well-being across all time points |
| Hurria 2006<sup>10</sup> | 20                  | ECOG 0–2 for participants to be eligibleGrade 0–1, 96% Grade 2, 4% | Participants treated with capcitabine has significantly fewer adverse effects during and at the completion of CT | NR                     | Global QoL (0–100) n=170 | 63.1±18.4 (standard CT) n=170 | Global QoL decreased across all time points within group but no information of P value (Participants treated with capcitabine had significantly better global QoL, role and social functioning, less fatigue, less nausea and vomiting, less constipation and better appetite, and less psychological distress than standard CT group. This difference had resolved by 12 months with no further difference at 24 months) |
| Kornblith 2011<sup>11</sup> | 21                  | ECOG 0–2 for participants to be eligibleGrade 0–1, 96% Grade 2, 4% | Participants treated with capcitabine has significantly fewer adverse effects during and at the completion of CT | NR                     | Global QoL (0–100) n=156 | 63.2±17.3 (capcitabine) n=156 | Global QoL decreased across all time points within group but no information of P value (Participants treated with capcitabine had significantly better global QoL, role and social functioning, less fatigue, less nausea and vomiting, less constipation and better appetite, and less psychological distress than standard CT group. This difference had resolved by 12 months with no further difference at 24 months) |
| Watters 2003<sup>12</sup> | NR                  | KPS—NR                        | During therapy: KPS declined during and by the completion of CT but did not differ from baseline at follow-up | NR                     | Global QoL (0–100) n=20 | 77±14 (6 months post-CT) n=20 | Global QoL decreased significantly from baseline to the time of completion of CT but improved at 6 months post-CT<sup>12</sup> Subscales | Selected older women tolerated anthracycline-based adjuvant CT for breast cancer well |

Continued
### Table 2 Continued

| Study                        | Functional status at baseline | Comorbid condition at baseline | Toxicity/adverse effect                                      | Supportive care where reported | Global or overall QoL scores (scale range) | Global or overall QoL scores if reported | Findings of global or overall QoL (Other QoL domains/subscales if reported) | Authors’ conclusions                                                                 |
|------------------------------|-------------------------------|-------------------------------|-------------------------------------------------------------|-------------------------------|-------------------------------------------|------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Perrone 2015                  |                               |                               | G-CSF and erythropoietin were used according to standard guidelines. G-CSF was also recommended for prophylaxis when grade ≥2 neutropenia occurred | No information on mean or median n=252 | No information on mean or median          |                                           | ▶ Global QoL decreased from baseline to midtreatment in both standard CMF and docetaxel groups but between-group difference was not significant. No information on within-group difference. Subscales: Physical, role, social and cognitive functioning decreased from baseline to midtreatment in both standard CMF and docetaxel groups but between-group differences were not significant. No information on within-group difference. (A statistically significant worsening with docetaxel was found for systemic therapy side effects, future perspective, nausea and vomiting, diarrhoea, appetite loss, upset by hair loss and body image domains)                                                                 | ▶ There was no significant interaction of treatment arms & geriatric scales measuring patients’ ability or comorbidities. Docetaxel is not superior to standard CMF in survival. Docetaxel worsens several QoL subscales and causes more non-haematological toxicity. |
| Baseline In the middle        | At the time of completion     | Follow-up period               |                                                             |                               |                                           |                                           |                                                                                     |                                                                                      |
| ECOG Grade 0, 83% Grade 1, 17%|                               |                               | Severe (grade ≥2) haematological toxicity was suffered by 70% of participants with CMF and 9% with docetaxel, while severe non-haematological toxicity was reported in 19% participants with CMF and 28% with docetaxel | G-CSF and erythropoietin were used according to standard guidelines. G-CSF was also recommended for prophylaxis when grade ≥2 neutropenia occurred | No information on mean or median n=252 | No information on mean or median          |                                           |                                                                                     |                                                                                      |
| No comorbidity               | 60%                           |                               |                                                             | No information on mean or median n=252 | No information on mean or median          |                                           |                                                                                     |                                                                                      |
| 1 comorbidity                | 31%                           |                               |                                                             | No information on mean or median n=252 | No information on mean or median          |                                           |                                                                                     |                                                                                      |
| ≥2 comorbidities             | 8%                            |                               |                                                             | No information on mean or median n=252 | No information on mean or median          |                                           |                                                                                     |                                                                                      |
| Gállego Pérez-Larraya 2011    | Baseline: KPS <70 for participants to be eligible | During therapy: 33% improved their KPS by ≥10, before disease progression | Grade 3 or 4 haematological toxicity 25%. Most adverse events were mild or moderate. According to MMSE, Patient’s cognitive function improved over time | No Information on mean or median n=59 | 1.4 points increase per month n=35       |                                           | ▶ Global QoL improved significantly over time* Subscales: Physical, role, social and cognitive functioning improved significantly over time* For QLQ-BN20, scores on motor dysfunction, drowsiness and bladder control improved over time before disease progression | ▶ There was no significant interaction of treatment arms & geriatric scales measuring patients’ ability or comorbidities. Docetaxel is not superior to standard CMF in survival. Docetaxel worsens several QoL subscales and causes more non-haematological toxicity. |
| Baseline: KPS ≥70 for patients to be eligible | During therapy: KPS declined over time | No severe adverse effects related to RT Corticosteroids and anticonvulsant agents, physical and psychological support, management by a palliative care team | No Information on mean or median n=59 | 1.4 points increase per month n=35 |                                           |                                           |                                                                                     |                                                                                      |
| KPS <70 for participants to be eligible | During therapy: KPS ≥70 for participants to be eligible | During therapy: KPS ≥70 for participants to be eligible | No severe adverse effects related to RT Corticosteroids and anticonvulsant agents, physical and psychological support, management by a palliative care team | No Information on mean or median n=59 | 1.4 points increase per month n=35 |                                           |                                                                                     |                                                                                      |
| Keime-Gübert 2007            |                               |                               |                                                             |                               |                                           |                                           | ▶ Global QoL did not deteriorate significantly over time (supportive care+RT) Subscales: During and after treatment, scores were significantly worse over time on physical, cognitive and social functioning, and fatigue and motor dysfunction* |
| Baseline In the middle        | At the time of completion     | Follow-up period               |                                                             |                               |                                           |                                           | ▶ Global QoL did not deteriorate significantly over time (supportive care+RT) Subscales: During and after treatment, scores were significantly worse over time on physical, cognitive and social functioning, and fatigue and motor dysfunction* |                                                                                      |
| KPS ≥70 for participants to be eligible | During therapy: KPS ≥70 for participants to be eligible | During therapy: KPS ≥70 for participants to be eligible | No severe adverse effects related to RT Corticosteroids and anticonvulsant agents, physical and psychological support, management by a palliative care team | No Information on mean or median n=59 | 1.4 points increase per month n=35 |                                           |                                                                                     |                                                                                      |
| Baseline In the middle        | At the time of completion     | Follow-up period               |                                                             |                               |                                           |                                           | ▶ Global QoL did not deteriorate significantly over time (supportive care+RT) Subscales: During and after treatment, scores were significantly worse over time on physical, cognitive and social functioning, and fatigue and motor dysfunction* |                                                                                      |
| KPS ≥70 for participants to be eligible | During therapy: KPS ≥70 for participants to be eligible | During therapy: KPS ≥70 for participants to be eligible | No severe adverse effects related to RT Corticosteroids and anticonvulsant agents, physical and psychological support, management by a palliative care team | No Information on mean or median n=59 | 1.4 points increase per month n=35 |                                           |                                                                                     |                                                                                      |
| Keime-Gübert 2007            |                               |                               |                                                             |                               |                                           |                                           | ▶ Global QoL did not deteriorate significantly over time (supportive care+RT) Subscales: During and after treatment, scores were significantly worse over time on physical, cognitive and social functioning, and fatigue and motor dysfunction* |                                                                                      |
| Baseline In the middle        | At the time of completion     | Follow-up period               |                                                             |                               |                                           |                                           | ▶ Global QoL did not deteriorate significantly over time (supportive care+RT) Subscales: During and after treatment, scores were significantly worse over time on physical, cognitive and social functioning, and fatigue and motor dysfunction* |                                                                                      |
| Study          | Functional status at baseline | Comorbid condition at baseline | Toxicity/adverse effect | Supportive care where reported | Global or overall QoL scores (scale range) | Global or overall QoL scores (Adjuvant chemotherapy and/or radiotherapy) | Findings of global or overall QoL (Other QoL domains/subscales if reported) | Authors’ conclusions |
|----------------|-----------------------------|--------------------------------|-------------------------|-------------------------------|-------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------|
| Minniti 2009²⁶ | Baseline: KPS ≥60 for participants to be eligible; KPS median 70; KPS did not change significantly during the study period | Diabetes 19% out of 43; Hypertension 33% out of 43; Cardiovascular disease 16% out of 43 | Grade 2–3 confusion and/or somnolence during or after RT 14% out of 43; Grade 3–4 haematological during CT 28% out of 43 (which led to the early discontinuation of CT in half of participants); Moderate-to-severe fatigue 35% out of 43; nausea 10% out of 43; constipation 22% out of 43; skin rash 9% out of 43 | Anticonvulsants and dexamethasone | Global QoL, (0–100): 58.3±3.7, n=36 | 54.3±5.1 (completion of RT) n=36; 57.3±6.8 (mid-CT; RT followed by CT) n=36 | Score of global health status did not change significantly; Subscales: Fatigue and constipation scales worsened slightly from baseline through treatment; Role and social functioning, and fatigue deteriorated significantly between baseline and the second follow-up | Temozolomide is well tolerated; The association of hypofractionated RT and temozolomide had no negative effect on QoL. |
| Minniti 2013²⁷ | KPS ≥60 for participants to be eligible; KPS median 70 | NR | NR | NR | Global QoL, (0–100): 61.5±20.8, n=65 | 60.0 (no information on SD) (1 month after RT and concomitant temozolomide) n=53; 72.0 (no information on SD) (6 months from the start of RT) n=27 | Global QoL improved significantly between baseline and 6 months from the start of RT (in the midst of adjuvant temozolomide); Subscales: Social and cognitive functioning improved significantly between baseline and 6 months from the start of RT; Fatigue worsened significantly between baseline and 4-month follow-up | A short course of RT in combination with temozolomide was associated with survival benefit (median survival and 1-year survival rates of 12.4 months and 58%, respectively) without a negative effect on QoL |
| Mohile 2011²⁸ | NR | NR | NR | NR | Overall QoL, (0–10): 2.07 (no information on SD) n=368 | 2.37 (no information on SD) n=368 | There was an increase of interference with QoL score after RT, however, no information about the P value; Subscales: The prevalence of memory difficulties and sleep disturbance, and the severity of fatigue and distress significantly increased over the course of RT | There were no differences in the change in interference with QoL between older and younger patients during RT |
| Arraras 2008b²⁹ | KPS mean 96.1 | NR | NR | NR | Global QoL, (0–100): 66.8±17.9, n=137 | 66.7±20.9 (1.5 months after completion of RT) n=126 | No change in global QoL score from baseline to last dose of RT but significantly improved from last dose to 1.5 months after RT; Subscales: There was a significant worsening of physical, cognitive and social functioning from baseline to last dose of RT, but physical functioning improved significantly from last dose to 1.5 months after RT | There was a tendency to a worsening of QoL at the end of the treatment, with a recovery in most scales in the follow-up measurement that could be due to RT low toxicity level |
| Study            | Functional status at baseline (functional status during adjuvant therapy if reported) | Comorbid condition at baseline | Toxicity/adverse effect | Supportive care where reported | Global or overall QoL scores (scale range) | Global or overall QoL scores Adjuvant chemotherapy and/or radiotherapy | Findings of global or overall QoL (Other QoL domains/subscales if reported) | Authors’ conclusions |
|------------------|---------------------------------------------------------------------------------------|-------------------------------|-------------------------|---------------------------------|------------------------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------|
| Bouvier 2008(1)  | NRI                                                                                   | NR                            | NR                      | NR                              | Global QoL 0–100: 60 (no information of SD) n=11 | No information on mean or median | No information on mean or median | ► Graph shows the mean scores of global QoL increased over time, but no information about the P value Subscales | ► Global QoL for patients with stage III colon cancer treated with adjuvant CT did not vary significantly from that of patients who did not receive CT across time |
| Chang 2012(1)    | ECOG Grade 0, 4.9% Grade 1, 63.4% Grade 2, 31.7% (data for the original sample of 82) | CACI ≤7, 75.6% Grade 3 hand-foot syndrome 25.6% (data for the original sample of 82) | Grade 3 or 4 haematological toxicity <1% Grade 3 hand-foot syndrome 25.6% (data for the original sample of 82) | NR                              | Global QoL 0–100: 59 (no information of SD) n=57 | No information on mean or median | No information on mean or median | ► No significant worsening of global QoL during CT Subscales | ► By using a tailored-dose escalation strategy, unnecessary dose reduction could be avoided without an increment of toxic effects in patients receiving capecitabine. The toxicity profiles were favourable. |
| Caffo 2003(1)    | NR                                                                                   | NR                            | The mean no. of daily stools progressively increased during the treatment | Participants experiencing grade 3–4 diarrhoea were given loperamide with adequate water and saline support. If loperamide was ineffective, treatment with octreotide was planned | Overall QoL (daily card) (1–4) No data reported for EORTC 2.11±0.75 n was not reported | 2.46±0.67 n was not reported | 2.55±1.05 n was not reported | ► Global QoL score improved progressively across study points, and from baseline to final evaluation (during RT), but no information about the P value | ► The authors’ conclusion is not related to QoL |
| Park 2013(1)     | ECOG 0–1 for participants to be eligible 0 comorbidity 71.2% Any comorbid conditions 28.8% | Grade 3 neutropaenia 39.4%, anaemia 4.5%, thrombocytopaenia 1.5% | NR                      | Global QoL 0–100: 53 (no information of SD) n=66 | No information on mean or median | No information on mean or median | No information on mean or median | ► Global QoL did not significantly deteriorate over time | ► Postoperative CT did not substantially reduce QoL in elderly patients with NSCLC |

*Significant difference reported by the study authors (P<0.05).
ADLs, activities of daily living; BMI, body mass index; BOMC, Blessed Orientation-Memory-Concentration test; CACI, Charlson-Age Comorbidity Index; CCI, Charlson Comorbidity Index; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; GDS, Geriatric Depression Scale; IADLs, instrumental activities of daily living; KPS, Karnofsky Performance Status Scale; MMSE, Mini-Mental State Examination; NCI CTC, National Cancer Institute Common Toxicity Criteria; NR, not reported; OARS, Older American Resources and Services Questionnaire; RT, radiotherapy.
Table 3  Results of the methodological quality assessment

| Studies                      | Sampling | Selection of QoL instrument | Data collection process | Response rate | Group comparison | Clarity of reporting | Quality score |
|------------------------------|----------|-----------------------------|-------------------------|---------------|------------------|----------------------|--------------|
| Arraras 2008a                | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Browall 2008                 | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Crivellari 2000              | O1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| B (O I) C M G H E A D F J K L |          |                              |                         |               |                  |                      | 11           |
| Dees 2000                    | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Hurria 2006                  | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Kornbith 2011                | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Watters 2003                 | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Penone 2015                  | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Gállego Pérez-Larraya 2011   | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Kéime-Guibert 2007           | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Minniti 2009                 | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Minniti 2013                 | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Mohile 2011                  | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Chang 2012                   | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Caffo 2003                   | B1       | 0                           | 0                       | 1             | 1                | 1                    | 0            |
| (only age and cancer diagnosis were reported) | (only among 30 respondents undergoing curative surgical resection for stage III cancer with 11 received adjuvant CT was reported) | (no information on dosage) | (only graphical information was reported) | (only graphical information was reported) | 9 |
| Continued                    |          |                              |                         |               |                  |                      | 11           |
| Chang 2012                   | B1       | 1                           | 1                       | 1             | 1                | 0                    | 0            |
| Caffo 2003                   | B1       | 0                           | 0                       | 1             | 1                | 1                    | 0            |
| (only age and cancer diagnosis were reported) | (only among 30 respondents undergoing curative surgical resection for stage III cancer with 11 received adjuvant CT was reported) | (no information on dosage) | (only graphical information was reported) | (only graphical information was reported) | 10 |
Table 3 Continued

| Sampling | Selection of QoL instrument | Data collection process | Response rate | Group comparison | Clarity of reporting | Determination of prognostic factor QoL | Quality score |
|----------|-----------------------------|-------------------------|---------------|------------------|---------------------|--------------------------------------|--------------|
|          |                             |                         |               |                  |                     |                                      |              |
| Park 2013 |                             |                         |               |                  |                     |                                      | 11           |

A, sociodemographic and medical data is described (eg, age, race, employment status, educational status, tumour stage at diagnosis, etc); B, inclusion and/or exclusion criteria are formulated; C, the process of data collection is described (eg, interview or self-report etc); D, the type of cancer treatment is described; E, the results are compared between two groups or more (eg, healthy population, groups with different cancer treatment or age, comparison with time at diagnosis, etc); F, mean or median and range or SD of time since diagnosis or treatment is given; G, participation and response rates for patient groups have to be described and have to be >75%; H, information is presented about patient/disease characteristics of responders and non-responders or if there is no selective response; I, a standardised or valid quality of life questionnaire is used; J, results are described for quality of life and for the physical, psychological and social domain; K, mean, median, SD or percentages are reported for the most important outcome measures (QoL); L, an attempt is made to find a set of determinants with the highest prognostic value (QoL); M, patient signed an informed consent form before study participation; n, no; O, the degree of selection of the patient sample is described.

Figure 2: Risk of bias summary for randomised controlled trials.

Other QoL measures

- Cheng KK-F, et al. BMJ Open 2018;8:e018101. doi:10.1136/bmjopen-2017-018101
- Sheperd et al. Lancet 2011;378:2102-2114.
- Dees et al. CA Cancer J Clin 2011;61:222-250.
- Hurria et al. J Clin Oncol 2007;25:2635-2642.
- Park et al. J Cancer Res Clin Oncol 2013;139:573-581.
- Arraras et al. J Support Oncol 2008;6:263-270.
- Perrone et al. J Pain Symptom Manage 2015;50:447-458.
- Karedal et al. Breast Cancer Res 2012;14:R57.
- Cribella et al. J Pain Symptom Manage 2007;33:694-701.
- Chiriboga et al. J Clin Oncol 2010;28:2987-2995.

Note that 75% and 75% of the participants finished the QoL assessment at baseline, immediately after the completion of chemotherapy, whereas 10% of the participants dropped out during and immediately after the completion of chemotherapy. Therefore, the completion of chemotherapy was reported to the QoL score after the completion of chemotherapy. After the completion of chemotherapy, the QoL score increased significantly from baseline to 12 months after the completion of chemotherapy.
revealed no significant differences in overall or in physical, social and emotional well-being as measured by Functional Assessment of Cancer Therapy-Breast (FACT-B) from baseline to immediately after and 6 months after completion of an anthracycline-based, taxane-based or CMF regimen. Note that 27% and 31% of the participants of this study suffered from grade 3 or 4 haematological and non-haematological toxicity, respectively.

Crivellari et al reported increased global QoL scores as measured by the Perceived Adjustment to Chronic Illness Scale (PACIS), during and 18 months after the completion of the CMF regimen. Note that the participants of this study had a low QoL score of 59 at baseline. Fewer than 10% of the participants manifested grade 3 toxicity.

### Glioblastoma

All four studies were conducted on participants with glioblastoma treated with temozolomide or focal hypofractionated radiotherapy or combined radiotherapy and temozolomide. These studies assessed QoL using the EORTC QLQ-C30. Gállego Pérez-Larraya et al reported statistically significant improvements in the global score and the physical, role, cognitive and social domain scores during the course of temozolomide. Note that 25% of

### Table 4 Risk of bias summary for non-RCTs (ROBINS-I)

| Studies                      | Preintervention | At intervention | Postintervention | Overall risk of bias     |
|------------------------------|-----------------|-----------------|------------------|--------------------------|
|                              | Bias due to confounding | Bias in selection of participants into the study | Bias in classification of interventions | Bias due to deviations from intended interventions | Bias due to missing data | Bias in measurement of outcomes | Bias in selection of the reported result |                                  |
| Arraras 2008a               | M               | M               | M                | M                        | M                        | M                        | Unclear                         | Low or moderate risk if bias for all domains |
| Browall 2008                | M               | M               | M                | S                        | M                        | M                        | Unclear                         | Serious risk of bias in at least one domain |
| Dees 2009                   | S               | S               | L                | M                        | M                        | M                        | Unclear                         | Serious risk of bias in at least one domain |
| Hurria 2006                 | M               | M               | L                | M                        | L                        | M                        | Unclear                         | Low or moderate risk if bias for all domains |
| Watters 2003                | S               | M               | L                | M                        | L                        | M                        | Unclear                         | Serious risk of bias in at least one domain |
| Gállego Pérez-Larraya 2011  | M               | M               | L                | M                        | S                        | S                        | Unclear                         | Serious risk of bias in at least one domain |
| Minniti 2009                | M               | M               | L                | M                        | L                        | M                        | Unclear                         | Low or moderate risk if bias for all domains |
| Minniti 2013                | M               | M               | L                | M                        | S                        | M                        | Unclear                         | Serious risk of bias in at least one domain |
| Mohile 2011                 | S               | M               | Unclear          | L                        | M                        | Unclear                         | Serious risk of bias in at least one domain |
| Arraras 2008b               | M               | S               | Unclear          | Unclear                  | M                        | M                        | Unclear                         | Serious risk of bias in at least one domain |
| Bouvier 2008                | S               | M               | Unclear          | L                        | M                        | Unclear                         | Serious risk of bias in at least one domain |
| Chang 2012                  | M               | M               | L                | M                        | M                        | M                        | Unclear                         | Low or moderate risk if bias for all domains |
| Caffo 2003                  | S               | S               | L                | Unclear                  | M                        | M                        | Unclear                         | Serious risk of bias in at least one domain |
| Park 2013                   | M               | M               | M                | M                        | M                        | M                        | Unclear                         | Low or moderate risk if bias for all domains |

C, critical risk; L, low risk; M, moderate risk; S, serious risk.
Table 5  Matrix of baseline and change of QoL scores, attrition rate, methodological quality score and RoB

| Type of cancer studies | QoL scale | Baseline | From baseline to the middle of adjuvant CT/or RT | From baseline to the time of completion of adjuvant CT/or RT | From baseline to postadjuvant CT/RT follow-up period | Attrition (last follow-up) where reported (%) | Methodological quality | Overall risk of bias judgement for non-RCTs |
|------------------------|-----------|----------|-----------------------------------------------|----------------------------------------------------------|------------------------------------------------|-----------------------------------------------|----------------------|---------------------------------------------|
| **Breast**              |           |          |                                               |                                                          |                                               |                                               |                      |                                             |
| RCTs                   |           |          |                                               |                                                          |                                               |                                               |                      |                                             |
| Kornblith 2011          | EORTC     | Standard CT 75.4 | ↓ (no information on P value) | ↓ (no information on P value) | ↑ (no information on P value) | 17 | 10 | (refer to RoB summary) |
| Capecitabine            |           | 76.5     | ↓ (no information on P value) | ↓ (no information on P value) | ↑ (no information on P value) | 18.6 |                      |                                             |
| Perrone 2015            | EORTC     | Standard CT (mean or median was not reported) | ↓ (narrative/graph; mean or median was not reported) | ↓ (narrative/graph; mean or median was not reported) | ↑ (no information on P value) | No information | 11 | (refer to RoB summary) |
| Docetaxel (mean or median was not reported) |           |          |                                               |                                                          |                                               |                                               |                      |                                             |
| Crivellari 2000         | PACIS     | Median 59 | ↑ (no information on P value) | ↑ (no information on P value) | |
| Non-RCTs               |           |          |                                               |                                                          |                                               |                                               |                      |                                             |
| Arraras 2008            | EORTC     | 59.5     | ↓ | ↑* ES 0.52 | 4.2 | 11 | low or moderate |
| Browall 2008            | EORTC     | 76       | ↓* ES 0.74 | ↓* ES 0.71 | ↓ (an improving trend) | 23.1 | 12 | serious |
| Dees 2000               | BCQ       | 7.65 on the scale of 0–10 | ↓ | | 36.4 | 10 | serious |
| Hurria 2006             | FACT-B    | 116 on the scale of 0–148 | 0 | ↑ | 2 | 12 | low or moderate |
| Watters 2003            | EORTC     | 78       | ↓ | ↓* ES 0.66 | ↓ (an improving trend) | 0 | 11 | serious |
| **Glioblastoma**        |           |          |                                               |                                                          |                                               |                                               |                      |                                             |
| RCT                     |           |          |                                               |                                                          |                                               |                                               |                      |                                             |
| Keime-Guibert 2007      | EORTC     | 62.9     | ↓ | ↓ (an improving trend) | 25.7 | 11 | (refer to RoB summary) |
| Non-RCTs                |           |          |                                               |                                                          |                                               |                                               |                      |                                             |

Continued
| Type of cancer studies | QoL scale | Baseline | From baseline to the middle of adjuvant CT/or RT | From baseline to the time of completion of adjuvant CT/or RT | From baseline to postadjuvant CT/RT follow-up period | Attrition (last follow-up) where reported (%) | Methodological quality | Overall risk of bias judgement for non-RCTs |
|------------------------|-----------|----------|-----------------------------------------------|----------------------------------------------------------|------------------------------------------------|-----------------------------------------------|----------------------|------------------------------------------|
| Gállego Pérez-Larraya 2011† | EORTC | Mean or median was not reported | ↑ (narrative; mean or median was not reported) | 40.7 | 11 | serious |
| Minniti 2009 | EORTC | 58.3 | ↓ | 0 | 12 | low or moderate |
| Minniti 2013 | EORTC | 61.5 | ↑ | 58.5 | 12 | serious |
| Mixed | | | | | | |
| Mohile 2011 | MD Anderson SI | 2.07 on the scale of 0–10 | ↑ (no information on P value) | 0 | 8 | serious |
| Prostate | | | | | | |
| Arraras 2008 | EORTC | 66.8 | 0 | ↑* ES=0.25 | 8 | 6 | serious |
| Colon cancer | | | | | | |
| Bouvier 2008 | EORTC | 60 | ↑ (graphical data; mean or median was not reported) | ↑ (graphical data; mean or median was not reported) | No information | 8 | serious |
| Chang 2012 | EORTC | 59 | ↓ (narrative; mean or median was not reported) | ↑ (narrative; mean or median was not reported) | 15.8 | 9 | low or moderate |
| Cervical | | | | | | |
| Caffo 2003 | Diary card | 2.11 on the scale of 1–4 | ↑ | ↑ | No information | 6 | serious |
| Lung | | | | | | |
| Park 2013 | EORTC | 53 | ↓ (narrative; mean or median was not reported) | ↓ (narrative; mean or median was not reported) | 9.1 | 11 | low or moderate |

* P< 0.05; ′0′ represents no change; ′↑′ denotes better QoL than baseline; ′↓′ represents worse QoL than baseline.
QoL scale is on the scale of 0–100 unless specified otherwise.
ES, effect size which was calculated for significant result and where mean, SD and sample size were available of the respective article.
BCQ, Breast Cancer Chemotherapy Questionnaire; EORTC, European Organization for Research and Treatment of Cancer; FACT-B, Functional Assessment of Cancer Therapy-Breast Cancer; PACIS, perceived adjustment to chronic illness scale.
the participants manifested grade 3–4 haematological toxicity in this study. Minniti et al also showed statistically significant improvements in the global score and the social and cognitive domain scores from baseline to 6 months from the start of radiotherapy (which was during the course of temozolomide). Both Keime-Guibert et al. and Minniti et al reported a decline in the global QoL at the completion of focal hypofractionated radiotherapy. With respect to the domain scores, these two studies reported statistically significantly lower scores for the physical, cognitive and social domains, respectively, during and after radiotherapy than at baseline. The participants in both studies were treated with corticosteroids and anticonvulsants as supportive care. Note that in the study by Minniti et al., the participants began with a lower QoL (score of 58.3) at baseline and that 14% of these participants developed grade 2 or 3 confusion and/or somnolence during or after radiotherapy.

Colon cancer

Two studies measured the global QoL with the EORTC QLQ-C30 at baseline and during and after chemotherapy in participants with colon cancer. In the study by Bouvier et al., the participants were treated with a fluorouracil/oxaliplatin/capcitabine regimen. This study reported an increase in the global QoL scores over time; however, no information about the P value was provided. Chang et al. found no significant worsening of the global and functional QoL during capecitabine treatment.

Prostate cancer

Arraras et al measured QoL by using the EORTC QLQ-C30 in participants treated with radiotherapy for prostate cancer. No difference in the global QoL score was observed from baseline to the last dose of radiotherapy, whereas a statistically significant improvement in the global score and social and cognitive domain scores from baseline to 6 months from the start of radiotherapy (which was during the course of temozolomide) was observed. Both Keime-Guibert et al. and Minniti et al. reported a decline in the global QoL at the completion of focal hypofractionated radiotherapy. With respect to the domain scores, these two studies reported statistically significantly lower scores for the physical, cognitive and social domains, respectively, during and after radiotherapy than at baseline. The participants in both studies were treated with corticosteroids and anticonvulsants as supportive care. Note that in the study by Minniti et al., the participants began with a lower QoL (score of 58.3) at baseline and that 14% of these participants developed grade 2 or 3 confusion and/or somnolence during or after radiotherapy.

Lung cancer

Park et al. measured the global QoL using the EORTC QLQ-C30 at baseline and 1 month after the completion of therapy with cisplatin plus vinorelbine or carboplatin plus paclitaxel in participants with resectable non-small cell lung carcinoma. In this study, the QoL score of 53 at baseline was low. No significant deterioration of the global QoL between baseline and the follow-up evaluation was observed. Severe haematological toxicity was manifested in 39% of the participants.

Other cancers

Mobahi et al studied different types of cancer, and QoL was measured before and after radiotherapy using an item of interference with overall QoL, together with the modified MD Anderson Symptom Inventory. In this study, the overall QoL score of 2.07 on the scale of 10 at baseline was low. A slightly higher overall QoL score was shown at the completion of radiotherapy (score of 2.37); however, no information about the P value was reported.

DISCUSSION

In the context of cancer, QoL by its nature is a patient’s overall appraisal of the effect of cancer and its treatment. It is a patient-centred, relevant and key clinical parameter that can assist and support clinicians in setting goals and mapping avenues for effective and tolerable cancer treatment regimens beyond extending patient survival. Although the 18 studies included in this systematic review had somewhat heterogeneous study designs, cancer populations and measurement scales and reporting parameters of QoL to permit data pooling for a meta-analysis and precise estimation, our results provide some insights that will contribute to a better understanding of the effects of adjuvant chemotherapy and/or radiotherapy on the QoL of elderly patients aged 65 years or above. Our review suggests that QoL during and after adjuvant chemotherapy and/or radiotherapy is maintained or improved in most patients with solid tumours.

For elderly patients with breast cancer, the non-significant negative change in the global or overall QoL was transient (during and immediately after chemotherapy or radiotherapy), as measured by the EORTC QLQ-C30, FACT-B and BCQ. No lasting adverse effect on QoL was observed after completion of the adjuvant treatment (overall low or moderate to serious RoB). Browall et al. and Watters et al. revealed an initial statistically significant decline (moderate ES), followed by progressive improvement in global QoL scores from baseline to 4–6 months after chemotherapy (overall serious RoB). The role and social domains of QoL was mostly impaired immediately after the completion of chemotherapy.

Another finding of this review is the significant increase in the global QoL during the course of temozolomide treatment in elderly patients with glioblastoma (overall low or moderate to serious RoB), but a decreasing trend in QoL immediately after the completion of radiotherapy and 3 months after radiotherapy. Note that the studies by Gállego Pérez-Larraya et al. and Minniti et al. had substantial amounts of missing data (>40%), mainly because of the rapid progression of the disease in the glioblastoma population. However, the approach of complete case evaluation used in the final QoL analysis could have led to a systematic bias in the estimation of the true effect of adjuvant therapy on QoL towards high QoL scores. Therefore, some caution should be taken in the interpretation of the significant QoL improvement during the course of adjuvant therapy of elderly patients with glioblastoma. Nevertheless, attrition bias is always an issue in clinical trials involving QoL assessments and longitudinal follow-ups.

Adjuvant chemotherapy or radiotherapy also does not seem to compromise the QoL of elderly patients with prostate, colon or cervical cancer. This review shows a uniform trend of stable or improved global or overall QoL over the course of adjuvant therapy and at follow-up evaluations across the studies with prostate, colon or cervical cancer population (overall serious RoB). A decreasing trend in global or overall
QoL during and immediately after the completion of cisplatin or carboplatin treatment in elderly patients with lung cancer was reported in one study (overall low-to-moderate RoB).\textsuperscript{33}

We expected altered functional status, comorbidities, adverse effects, haematological status and liver and renal functional status to co-vary with the effect of adjuvant therapy on QoL and hence, to be plausible confounding factors in the geriatric and adjuvant settings. However, as is the case in non-RCT settings, adjuvant therapy was allocated during the course of usual treatment decisions. The non-RCTs included in this review might suffer from the methodological drawbacks of uncontrolled confounding factors at baseline and even during the follow-up. Because no attempt was made to control confounding factors with a stratified design and analysis, caution is warranted in the interpretation of the results. Nevertheless, we found it difficult to discern whether the short period of QoL impairment and the stable or improved QoL over the course of adjuvant therapy and after treatment were due to the relatively low treatment toxicities, the relatively few morbid conditions or other reasons. The fact that, where reported, the QoL of elderly patients was maintained or improved over the course of treatment, despite the haematological toxicity across studies,\textsuperscript{20 23 24 33} suggests that stable or improved QoL is unlikely to be attributable to relatively low treatment toxicity. Alternatively, elderly patients with cancer who undergo adjuvant therapy may experience adverse effects but can tolerate them with a limited effect on their QoL. This finding may also be attributed to the tendency of certain elderly patients to complain less and endure the relatively high morbidity associated with adverse effects.\textsuperscript{5} Elderly patients may also have a positive perception of the adjuvant therapy and may adjust better to the treatment. Stone \textit{et al} examined the association between global well-being and the age profile of 340,847 people and showed that people aged over 50 years have increased global well-being and positive emotions even in the face of a decline in the physical health.\textsuperscript{34} Another possible explanation for the stable or improved QoL could be the response shift phenomenon, in which patients experience a shift in how they appreciate their QoL over time as a result of the changes in their internal standards of measurement, values or definition of QoL.\textsuperscript{35 36} A future qualitative study is needed to explore in detail QoL perception and experiences in adjuvant settings and adjustment to the treatment among elderly patients with cancer. Nevertheless, for studies that reported a stable global or overall QoL (ie, no difference in the means) across time, a small sample size and attrition bias might limit the statistical power to detect the differences between the baseline and the follow-up evaluations.\textsuperscript{19 21 23 25 31} It could also be argued that another possible bias was the poor sensitivity of the generic QoL measures to tap dimensions of health status that are particularly salient to elderly patients with cancer during adjuvant therapy. While we cannot rule out the possible bias, in future clinical trials and observational studies attempts should be made to use geriatric oncology-specific QoL measures such as EORTC-QLQ-ELD14 to validate the review results.\textsuperscript{37} Furthermore, the samples of the included studies appear highly functional at baseline,\textsuperscript{16–23 25–33} so these studies may be subject to a selection bias pertaining to under-representation of less healthy older patients and those with limited expectations of treatment benefits.\textsuperscript{3}

**CONCLUSIONS**

This review suggests that a negative change in QoL was short-lived during adjuvant chemotherapy for some elderly patients with breast cancer. Adjuvant chemotherapy and radiotherapy may not have detrimental effects on global or overall QoL and other QoL domains in most elderly patients with solid tumours. These findings could be translated to help future elderly patients better understand the impact of adjuvant therapy on their QoL, and hence make better treatment decisions. Nevertheless, our review results should be viewed with caution because of RoB within and across the included studies. In addition, heterogeneity in study design and measurement of QoL, and lack of availability of data limit the pooling of data for meta-analysis and affect the robustness of the evidence synthesis. An attempt was made to contact the study authors for data, but without success. There is also a possibility of incompleteness of evidence because of unclear bias of the selection of reported result and the search of this review did not include grey literature, unpublished studies, ongoing clinical trials and theses and dissertations. Larger and well-designed studies of elderly patients in different cancer settings are warranted to validate these review results and to further build evidence to advance the current knowledge base. These studies should include and stratify elderly patients by functional status, comorbid conditions, geriatric syndromes and prognosis to be more representative of the real-world population and improve the research validity. Future studies should also include a detailed profile of the cytotoxic effects of chemotherapy and radiotherapy to allow a full exploration of the direct and indirect effects of adjuvant therapy on QoL. In future systematic reviews, if sufficient data are available, meta-regression should also be conducted to examine the association and interaction between the confounding factors and the QoL.

**Acknowledgements** The authors would like to thank Teo Desrene Rui Ling (TDRL), Research Assistant, for her work in literature search, eligibility assessments and study selection.

**Contributors** CKK-F, KR contributed to the conception or design of the work, and analysis and interpretation of data. CKK-F is responsible for drafting the manuscript. KR critically reviewed and revised the manuscript for important intellectual content. LEY-T contributed to the acquisition of data and critical revision of the manuscript for intellectual content. CKK-F, LEY-T, KR provided final approval of the version to be published.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
43. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30:473–83.

44. Taphoorn MJ, Claassens L, Aaronson NK, *et al.* An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. *Eur J Cancer* 2010;46:1033–40.

45. Cleeland CS, Mendoza TR, Wang XS, *et al.* Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. *Cancer* 2000;89:1634–46.

46. Fraser SC, Ramirez AJ, Ebbs SR, *et al.* A daily diary for quality of life measurement in advanced breast cancer trials. *Br J Cancer* 1993;67:341–6.

47. Bergman B, Aaronson NK, Ahmedzai S, *et al.* The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. *Eur J Cancer* 1994;30A:635–42.